When someone mentions aging, you may think of visible changes, like graying hair. Scientists can see signs of aging in cells, too. Understanding how basic cell processes are involved in aging is a first step to help people lead longer, healthier lives. NIGMS-funded researchers are discovering how aging cells change and applying this knowledge to health care.
Discovering the Wisdom of Worms
C. elegans with a ribosomal protein glowing red and muscle fibers glowing green. Credit: Hannah Somers, Mount Desert Island Biological Laboratory.
Aric Rogers, Ph.D., and Jarod Rollins, Ph.D., assistant professors of regenerative biology and medicine at Mount Desert Island (MDI) Biological Laboratory in Bar Harbor, Maine, are investigating aging by studying a tiny roundworm, Caenorhabditis elegans. Researchers often study C. elegans because, though it may seem drastically different from humans, it shares many genes and molecular pathways with us. Plus, its 2- to 3-week lifespan enables researchers to quickly see the effects of genetic or environmental factors on aging.
Drs. Rogers and Rollins investigate how C. elegans expresses genes differently under dietary restriction, enabling it to live longer. Understanding how genes are expressed when organisms live an extended life sheds light on the genetics underlying aging. This information could help researchers develop drugs or behavior modification programs that prolong life and delay the onset of age-related diseases such as heart disease, diabetes, cancer, and dementia.
NIGMS and Scholastic bring you our latest issue of Pathways, which focuses on superbugs—infectious microbes that can’t be fought off with medicines. Viruses that can’t be prevented with vaccines, such as the common cold, and antibiotic-resistant bacteria both fall into this category.
Pathways, designed for students in grades 6 through 12, is a collection of free resources that teaches students about basic science and its importance to health, as well as exciting research careers.
Sepsis is the body’s overactive and extreme response to an infection. It’s unpredictable, can progress rapidly, and affects more than 1.7 million people in the United States each year. Without prompt treatment, it can lead to tissue damage, organ failure, and death. NIGMS supports state-of-the-art sepsis research, including the development of rapid diagnostics and new therapeutics. September is Sepsis Awareness Month, and we’re highlighting a few resources that offer more information about this condition.
Our infographic provides details at a glance on basic statistics and the future of sepsis research. It’s also available in Spanish.
As part of its commitment to cultivate a diverse and inclusive scientific workforce, NIGMS continues to nurture relationships between teaching institutions and American Indian communities nationwide to ignite student interest in biomedical science and encourage research careers. This post highlights one such collaboration between NIGMS-supported centers at Montana State University (MSU) in Bozeman and the Blackfeet Nation, a tribe of nearly 18,000 members that’s one of the largest in the United States.
Neha John-Henderson, Ph.D., Montana State University. Credit: Kelly Gotham.
Neha John-Henderson, Ph.D. , an MSU assistant professor of psychology, first met Blackfeet Community College (BCC) students through Agnieszka Rynda-Apple, Ph.D., an MSU assistant professor of microbiology and immunology who already had a working relationship with the Blackfeet community. For about a year, Drs. John-Henderson and Rynda-Apple visited BCC interns and faculty supervisor Betty Henderson-Matthews monthly to help them interpret data collected for a student-developed project. While completing this project on the link between stress and health on the Blackfeet reservation, the researchers developed relationships with the students and faculty. They listened closely to the students’ stories, experiences, and career aspirations.
Recent news headlines are awash in references to “modeling the spread” and “flattening the curve.” You may have wondered what exactly this means and how it applies to the COVID-19 pandemic. Infectious disease modeling is part of the larger field of computer modeling. This type of research uses computers to simulate and study the behavior of complex systems using mathematics, physics, and computer science. Each model contains many variables that characterize the system being studied. Simulation is done by adjusting each of the variables, alone or in combination, to see how the changes affect the outcomes. Computer modeling is used in a wide array of applications, from weather forecasting, airplane flight simulation, and drug development to infectious disease spread and containment.
Sepsis is a serious medical condition caused by an overwhelming response to infection that damages tissues and organs. It’s unpredictable, progresses quickly, can strike anyone, and is a leading cause of hospital-related deaths. In the U.S. alone, nearly 270,000 people die each year from sepsis. Those who survive sepsis often end up in the hospital again, and some have long-term health complications. Early treatment is key for many patients to survive sepsis, yet doctors can’t easily diagnose it because it’s so complex and each patient is different.
Despite decades of research, sepsis remains a poorly understood condition with limited diagnostic tools and treatment. To tackle these obstacles, scientists Vincent Liu, Christopher Seymour, and Hallie Prescott have started using a “big data” approach, which relies on complex computer programs to sift through huge amounts of information. In this case, the computers analyze data such as demographic information, vital signs, and routine blood tests in the electronic health records of sepsis patients. The goal is to find patterns in the data that might help doctors understand, predict, and treat sepsis more effectively.
Brain injuries, cancer, infections, and wound healing are some of the complex and pressing health concerns we face today. Understanding the basic science behind these diseases and biological processes is the key to developing new treatments and improving patient outcomes. Physician scientists—medical doctors who also conduct laboratory research—are essential to turning knowledge gained in the lab into innovative treatments, surgical advances, and new diagnostic tools.
In this blog, we highlight the work and impact of three surgeon scientists funded by NIGMS at different stages in their careers: Dr. Nicole Gibran (current grantee), Dr. Rebecca Minter (former grantee), and Dr. Carrie Sims (former grantee). Their work, despite the historical underrepresentation of women in the physician scientist training community, has led to revolutionary surgical treatments, new therapeutics, better screening, and improved quality of life for patients.
Credit: Rommie Amaro, Jacob Durrant, Adam Gardner, and colleagues.
Ah, December—a month suffused with light-filled holidays, presents, parties . . . and the spread of colds and flu. This playful image uses a festive approach to the serious science of understanding and finding ways to combat the flu virus.
Although not as well-known as other medical conditions, sepsis kills more people in the United States than AIDS, breast cancer, or prostate cancer combined. Sepsis is body-wide inflammation, usually triggered by an overwhelming immune response to infection. Though doctors and medical staff are well-aware of the condition—it is involved in 1 in 10 hospital deaths—the condition is notoriously hard to diagnose. In this video, sepsis expert Sarah Dunsmore, a program director with the National Institute of General Medical Sciences (NIGMS), describes what sepsis is and how to recognize it, what kinds of patients are most at risk, and what NIGMS is doing to reduce the impact of this deadly condition.
Sepsis is a serious medical condition caused by an overwhelming immune response to infection. The body’s infection-fighting chemicals trigger widespread inflammation, which can lead to blood clots and leaky blood vessels. As a result, blood flow is impaired, depriving organs of nutrients and oxygen. In severe cases, one or more organs fail. In the worst cases, blood pressure drops, the heart weakens, and the patient spirals toward septic shock. Once this happens, multiple organs—lungs, kidneys, liver—may quickly fail, and the patient can die.
Because sepsis is traditionally hard to diagnose, doctors do not always recognize the condition in its early stages. In the past, it has been unclear how quickly sepsis needs to be diagnosed and treated to provide patients with the best chance of surviving.
Credit: University of Pittsburgh.
Now we may have an answer: A large-scale clinical study, published recently in the New England Journal of Medicine, found that for every hour treatment is delayed, the odds of a patient’s survival are reduced by 4 percent. Christopher Seymour, assistant professor of critical care and emergency medicine at the University of Pittsburgh, and his team analyzed the medical records of nearly 50,000 sepsis patients at 149 clinical centers to determine whether administering the standard sepsis treatment—antibiotics and intravenously administered fluids—sooner would save more lives.
I spoke with Seymour about his experience treating sepsis patients and his research on the condition, including the new study.
CP: How big a public health problem is sepsis?
CS: Our recent work with the Centers for Disease Control and Prevention suggests there might be as many as 2 million sepsis cases in the United States each year. I can share personally that sepsis, or septic shock, is far and away the most common life-threatening condition that I treat in the ICU (intensive care unit). It’s quite devastating, particularly among our elders, and it requires prompt care. Although the mortality rate may be decreasing, it’s still quite high. About 1 in 10 patients with sepsis don’t survive their hospital stay. Even young, healthy people can succumb from sepsis. And if you’re fortunate to survive, you can have significant problems with cognitive and physical function for many months to years down the line.
Unfortunately, the incidence of sepsis may even be increasing. More patients are surviving serious illnesses that used to be fatal. They’re alive, but their health is compromised, so they are at higher risk for sepsis. Also—and this is a positive—we are seeing greater recognition and increased reporting of sepsis. Both factors probably contribute to the higher numbers of reported sepsis cases.
CP: What are some of the biggest challenges in fighting sepsis?
CS: The first challenge is public awareness. It’s important that the public knows the word sepsis, that they’re familiar with sepsis being a life-threatening condition that results from an infection, and that they know it can strike anyone—young, old, healthy, or sick. But it’s also important to know that not every infection is septic, nor will every cut or abrasion lead to life-threatening organ dysfunction.
Another part of the problem is that sepsis is not as easy for patients to recognize as, say, myocardial infarction (heart attack). When patients clutch their chest in pain, they intuitively recognize what’s happening. Patients frequently don’t recognize that they’re septic. People should know that when they have an infection or take antibiotics as an outpatient, and they’re starting to feel worse or having other new symptoms, they may be at risk of sepsis. They should go to the emergency department or seek medical help.
The second challenge in fighting sepsis is that it’s just hard to diagnose, even for well-trained clinicians. Both issues can lead to delays in care, the most important of which is the delay in treatment with antibiotics.
CP: Tell me about your recent clinical trial. What question did you set out to answer?
CS: There’s been a lot of interest in the early recognition and treatment of sepsis over the past decade. Recently, the National Institutes of Health/National Institute of General Medical Sciences funded a large, multicenter trial called ProCESS, which tested various strategies for treating sepsis. This trial told us that a standardized sepsis protocol among people who had already received antibiotics didn’t necessarily change survival rates. But what it left unanswered was the very important question of when the patient first arrives at the emergency department, how fast do we need to provide antibiotics and fluids for the best possible outcome?
C. elegans with a ribosomal protein glowing red and muscle fibers glowing green. Credit: Hannah Somers, Mount Desert Island Biological Laboratory.
Cover of Pathways student magazine.
Credit: Murray Foubister. 
Neha John-Henderson, Ph.D., Montana State University. Credit: Kelly Gotham.
View the 
